Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
Grupo Aeroportuario del Sureste SAB de CV
XMUN:AED
|
MX |
|
Biofrontera Inc
NASDAQ:BFRI
|
US |
|
A
|
Amerisafe Inc
F:A3I
|
US |
Its concession-based airport portfolio has historically combined profitable passenger-linked operations with recurring investment needs and positive operating cash generation; cash has also supported distributions. Capital spending and acquisitions, however, can make post-investment cash conversion vary substantially.
Acquisitions of U.S. commercial operations and Brazil & Others materially expanded the reporting perimeter and increased debt funding; the latest quarter includes only one month of CPC operations, so its normalized contribution is not yet visible. This changes the near-term financing and cash-conversion profile, though the core concession economics remain intact.
Whether operating cash flow from the expanded portfolio covers recurring capital spending while debt levels stabilize.
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 9.8B | 12.6B | 15.4B | 16.8B | 12.6B | 18.8B | 25.3B | 25.8B | 31.3B | 37.2B | |
| (4.6B) | (10.9B) | (7.5B) | (8.3B) | (9.3B) | (9.9B) | (10.7B) | (10.3B) | (13.5B) | (19.9B) | |
| 5.1B | 1.7B | 7.9B | 8.5B | 3.4B | 8.9B | 14.6B | 15.6B | 17.8B | 17.3B | |
| (204.8m) | (204.4m) | (100.6m) | (45.5m) | (74.1m) | (263.2m) | (287.1m) | (319.2m) | (319.6m) | (346m) | |
| (204.8m) | (204.4m) | (235.3m) | (250.2m) | (232.9m) | (263.2m) | (287.1m) | (319.2m) | (319.6m) | (346m) | |
| — | — | 134.6m | 204.7m | 158.9m | 0 | — | 0 | 0 | — | |
| 4.9B | 1.5B | 7.8B | 8.5B | 3.3B | 8.7B | 14.4B | 15.2B | 17.5B | 17B | |
| 98.8m | (119.5m) | (862.3m) | (819.6m) | (420.5m) | (531.6m) | (613.4m) | (623.4m) | 2.9B | (2B) | |
| 126.2m | 618.8m | 1.2B | 1.1B | 926.3m | 842.4m | 855.5m | 1.1B | 826.7m | 1.5B | |
| — | — | — | — | — | — | 346.2m | — | — | — | |
| — | 7B | — | — | — | — | — | — | — | 0 | |
| 5B | 8.4B | 6.9B | 7.7B | 2.9B | 8.1B | 14.1B | 14.6B | 20.4B | 15B | |
| (1.4B) | (1.6B) | (1.8B) | (2B) | (729.2m) | (1.7B) | (3.4B) | (3.9B) | (6.3B) | (4B) | |
| 3.6B | 6.8B | 5.1B | 5.7B | 2.1B | 6.4B | 10.6B | 10.7B | 14B | 10.9B | |
| — | (915.7m) | (132.2m) | (217.8m) | (154.2m) | (413.8m) | (659.4m) | (472.2m) | (479m) | (435.8m) | |
| 3.6B | 5.8B | 5B | 5.5B | 2B | 6B | 10B | 10.2B | 13.6B | 10.5B | |
| 12.10 | 19.45 | 16.63 | 18.22 | 6.57 | 19.95 | 33.29 | 34.01 | 45.17 | 34.96 |
© 2026 Alpha Spread Limited. All Rights Reserved.
www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.
Alpha Spread
Preferences
We rebuilt our DCF valuation models from the ground up and upgraded how Intrinsic Value is calculated. Alpha Spread now selects the method that best fits each company.
You can now see how the new methodology performed across thousands of stocks on our new Valuation Backtest page. We update the results at the end of every month.
By using Alpha Spread you are agreeing to our Terms of Service and Privacy Policy.
Already have an account? Sign in
Stock intrinsic value is the real worth of a company's stock, based on its financial health and performance.
Instead of looking at the stock's current market price, which can change due to people's opinions and emotions, intrinsic value helps us understand if a stock is truly a good deal or not.
By focusing on the company's actual financial strength, like its earnings and debts, we can make better decisions about which stocks to buy and when.
Read more
